[go: up one dir, main page]

BRPI0400375A - Processo para remover vìrus em soluções de fibrinogênio para aplicação terapêutica e fibrinogênio obtido pelo dito processo - Google Patents

Processo para remover vìrus em soluções de fibrinogênio para aplicação terapêutica e fibrinogênio obtido pelo dito processo

Info

Publication number
BRPI0400375A
BRPI0400375A BR0400375-6A BRPI0400375A BRPI0400375A BR PI0400375 A BRPI0400375 A BR PI0400375A BR PI0400375 A BRPI0400375 A BR PI0400375A BR PI0400375 A BRPI0400375 A BR PI0400375A
Authority
BR
Brazil
Prior art keywords
fibrinogen
therapeutic application
solutions
adjusted
removing viruses
Prior art date
Application number
BR0400375-6A
Other languages
English (en)
Inventor
Pere Ristol Debart
Jesus Fernandez Rodrigues
Original Assignee
Probitas Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probitas Pharma Sa filed Critical Probitas Pharma Sa
Publication of BRPI0400375A publication Critical patent/BRPI0400375A/pt
Publication of BRPI0400375B1 publication Critical patent/BRPI0400375B1/pt
Publication of BRPI0400375B8 publication Critical patent/BRPI0400375B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0017—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PROCESSO PARA REMOVER VìRUS EM SOLUçõES DE FIBRINOGêNIO PARA APLICAçãO TERAPêUTICA E FIBRINOGêNIO OBTIDO PELO DITO PROCESSO". O processo inicia-se com uma solução de fibrinogênio purificada ajustada, a solução purificada ajustada é congelada e, então, descongelada para uma temperatura entre 5 e 20<198>C, os materiais não dissolvidos associados com o fibrinogênio são subseq³entemente separados, a temperatura é ajustada e a solução resultante é finalmente submetida a nanofiltragem utilizando-se filtros para uma dimensão de poro menor do que 35 nm.
BRPI0400375A 2003-03-06 2004-03-02 processo para remover vírus em soluções de fibrinogênio para aplicação terapêutica BRPI0400375B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200300538A ES2214967B1 (es) 2003-03-06 2003-03-06 Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.

Publications (3)

Publication Number Publication Date
BRPI0400375A true BRPI0400375A (pt) 2005-01-04
BRPI0400375B1 BRPI0400375B1 (pt) 2018-05-08
BRPI0400375B8 BRPI0400375B8 (pt) 2021-05-25

Family

ID=32749109

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0400375A BRPI0400375B8 (pt) 2003-03-06 2004-03-02 processo para remover vírus em soluções de fibrinogênio para aplicação terapêutica

Country Status (15)

Country Link
US (2) US7442308B2 (pt)
EP (1) EP1457497B1 (pt)
JP (1) JP4272562B2 (pt)
AR (1) AR043238A1 (pt)
AT (1) ATE410438T1 (pt)
AU (1) AU2004200745B8 (pt)
BR (1) BRPI0400375B8 (pt)
CA (1) CA2459690C (pt)
CL (1) CL2004000261A1 (pt)
DE (1) DE602004016900D1 (pt)
ES (2) ES2214967B1 (pt)
MX (1) MXPA04001829A (pt)
NZ (1) NZ531328A (pt)
PL (1) PL1457497T3 (pt)
PT (1) PT1457497E (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US20120177610A1 (en) * 2007-09-19 2012-07-12 Kieu Hoang Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins
PT2242479E (pt) 2007-12-28 2011-11-25 Baxter Int Filtração de proteínas por contrapressão
WO2010059232A1 (en) 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
CN102365368B (zh) * 2009-03-27 2014-07-30 旭化成医疗株式会社 高浓度单克隆抗体溶液中的病毒去除方法
CN106046147B (zh) 2010-09-20 2019-11-19 欧克塔医药公司 纤维蛋白原生产方法
EP2825555B1 (en) 2012-03-13 2017-07-12 Octapharma AG Mproved process for production of fibrinogen and fibrinogen produced thereby
MX347319B (es) * 2012-06-21 2017-04-21 Baxalta Inc Filtracion de virus de medio de cultivo celular.
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US10221220B2 (en) 2014-06-12 2019-03-05 Biosyn Arzneimittel Gmbh Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents
PL3154578T3 (pl) 2014-06-12 2019-07-31 Biosyn Arzneimittel Gmbh Sposoby wytwarzania bezpiecznych biologicznie produktów KLH nowej generacji stosowanych do leczenia raka, opracowywania skoniugowanych szczepionek terapeutycznych i jako środków prowokujących
KR101841587B1 (ko) 2016-01-12 2018-05-14 주식회사 녹십자홀딩스 피브리노겐의 정제방법
US20190167823A1 (en) * 2016-08-09 2019-06-06 Asahi Kasei Medical Co., Ltd. Method for treating solution contaminated with porcine circoviruses
FR3090321B1 (fr) 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
CN111848783B (zh) * 2020-07-29 2023-07-04 同路生物制药有限公司 一种人纤维蛋白原的制备方法
CN116744986A (zh) * 2020-12-25 2023-09-12 广州倍绣生物技术有限公司 纤维蛋白原除菌过滤
JP7645133B2 (ja) * 2021-06-04 2025-03-13 Ｋｍバイオロジクス株式会社 血液凝固第ｘｉｉｉ因子を含むフィブリノゲンの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US511154A (en) * 1893-12-19 Feed-gage for printing-presses
DE2624373C2 (de) * 1976-05-31 1983-02-03 Arnold Dr. 8782 Karlstadt Seufert Verfahren zur Herstellung von steril filtriertem Kryopräzipilat mit einer Anreicherung des Faktors VIII
FR2563357B1 (fr) * 1984-04-18 1987-12-04 Cormier Bernard Panneau de signalisation routiere
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
US5330974A (en) * 1993-03-01 1994-07-19 Fibratek, Inc. Therapeutic fibrinogen compositions
JP3867931B2 (ja) * 1993-11-08 2007-01-17 財団法人化学及血清療法研究所 液状フィブリノゲン製剤
US5506127A (en) * 1994-09-21 1996-04-09 Proba; Zbigniew Therapeutic grade thrombin produced by chromatography
EP0860444A1 (en) 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
US5981254A (en) * 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
FR2772381B1 (fr) * 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
ES2156731B1 (es) * 1999-05-31 2002-02-16 Grifols Grupo Sa Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
US6270672B1 (en) * 1999-08-06 2001-08-07 Baxter Aktiengesellschaft Devices and methods for removing pathogens from biological fluids
CN1192781C (zh) 1999-12-20 2005-03-16 三菱制药株式会社 用多孔膜处理的无病毒血浆蛋白组合物及其生产方法
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
JP2001335509A (ja) * 2000-05-31 2001-12-04 Nihon Pharmaceutical Co Ltd フィブリノーゲンを含有する溶液のウイルス除去法
IL136552A (en) * 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
DE10211632A1 (de) * 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration

Also Published As

Publication number Publication date
ES2214967B1 (es) 2005-06-16
BRPI0400375B1 (pt) 2018-05-08
ATE410438T1 (de) 2008-10-15
AR043238A1 (es) 2005-07-20
MXPA04001829A (es) 2004-09-08
JP4272562B2 (ja) 2009-06-03
EP1457497A1 (en) 2004-09-15
CL2004000261A1 (es) 2005-03-18
US7442308B2 (en) 2008-10-28
US20080274974A1 (en) 2008-11-06
PT1457497E (pt) 2008-12-10
US20040173527A1 (en) 2004-09-09
CA2459690C (en) 2010-11-02
PL1457497T3 (pl) 2009-06-30
DE602004016900D1 (de) 2008-11-20
AU2004200745B8 (en) 2009-01-08
AU2004200745A1 (en) 2004-09-23
ES2214967A1 (es) 2004-09-16
NZ531328A (en) 2004-10-29
EP1457497B1 (en) 2008-10-08
AU2004200745B2 (en) 2008-07-03
CA2459690A1 (en) 2004-09-06
ES2312944T3 (es) 2009-03-01
JP2004269529A (ja) 2004-09-30
BRPI0400375B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BRPI0400375A (pt) Processo para remover vìrus em soluções de fibrinogênio para aplicação terapêutica e fibrinogênio obtido pelo dito processo
BR0308385A (pt) Cristais de ácido (met) acrìlico e processo para produzir e purificar ácido (met) acrìlico aquoso
BR0114846A (pt) Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
BR0207811A (pt) Compostos de uréia aril e heteroaril substituìdos úteis no tratamento de doenças
BR0214313B1 (pt) processo contÍnuo para produÇço de isolado de proteÍna de semente oleaginosa
BR0315166A (pt) Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
BR0316776A (pt) Formula para anti-infeccioso tópico
BR0316868A (pt) Processo para a produção de pró-medicamentos de nucleosìdeo-3&#39;
EP1559814A4 (en) PROCESS FOR PRODUCING CRYSTALLINE CORE AND METHOD FOR SCREENING CRYSTALLIZATION CONDITIONS
BR112015023313A2 (pt) métodos para purificação de 5-(halometil)furfural
BRPI0504445A (pt) composição de trombina e processo para a sua preparação
BR0204286A (pt) Cura de placas positivas
BR0212925A (pt) Derivados de idol como inibidores de cox ii
PE103799A1 (es) Procedimiento de purificacion de mesilato de alatrofloxacino
WO2003028665A3 (en) Methods for the purification of levofloxacin
BR0207414A (pt) Método para remover impurezas de ácido 2-nitro-4-metil-sulfonilbenzóico, ácido 2-nitro-4-metilsulfonilbenzóico purificado, processo para fabricação de mesotriona, e, mesotriona ames-negativo
AR048279A1 (es) La forma ii cristalina de cabergolina
WO2003045329A3 (en) Methods for the purification of levofloxacin
BRPI0507886A (pt) método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o
WO2003014112A1 (en) Crystal and process for producing the same
EA200401032A1 (ru) Антиинфарктные молекулы
AR058361A1 (es) Composiciones lifolizadas de un compuesto de triazolopirimidina
JP2004532111A5 (pt)
BR0312604A (pt) ácidos imido-alcanpercarboxìlicos, composições, e, processo para a preparação e uso de ácidos imido-alcanpercarboxìlicos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: GRIFOLS, S.A. (ES)

Free format text: ALTERADO DE: PROBITAS PHARMA, S.A.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: GRIFOLS, S.A. (ES)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.